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A B S T R A C T
Background: The ﬁrst evidence that the hazard ratio (HR) for methadone-speciﬁc death rises more steeply with
age-group than for all drug-related deaths (DRDs) came from Scotland’s cohort of 33,000 methadone-pre-
scription clients. We aim to examine, for England, whether illicit opioid users’ risk of methadone-speciﬁc death
increases with age; and to pool age-related HRs for methadone-speciﬁc deaths with those for Scotland’s me-
thadone-prescription clients.
Methods: The setting is all services in England that provide publicly-funded, structured treatment for illicit
opioid users, the methodology linkage of the English National Drug Treatment Monitoring System and mortality
database, and key measurements are DRDs, methadone-speciﬁc DRDs, or heroin-speciﬁc DRDs, by age-group and
gender, with proportional hazards adjustment for substances used, injecting status and periods in/out of
treatment.
Results: Linkage was achieved for 129,979 adults receiving prescribing treatment modalities for opioid depen-
dence during April 2005 to March 2009 and followed-up for 378,009 person-years (pys).
There were 1,266 DRDs: 271 methadone-speciﬁc (7 per 10,000 pys: irrespective of gender) and 473 heroin-
speciﬁc (15 per 10,000 pys for males, 7 for females). Methadone-speciﬁc DRD-rate per 10,000 person-years was
3.5 (95% CI: 2.7–4.4) at 18–34 years, 8.9 (CI: 7.3–10.5) at 35–44 years and 18 (CI: 13.8–21.2) at 45+ years;
heroin-speciﬁc DRD-rate was unchanged with age.
Relative to 25–34 years, pooled HRs for UK clients’ methadone-speciﬁc deaths were: 0.87 at< 25 years (95%
CI: 0.56–1.35); 2.14 at 35–44 years (95% CI: 1.76–2.60); 3.75 at 45+ years (95% CI: 2.99–4.70).
Conclusion: International testing and explanation are needed of UK’s sharp age-related increase in the risk of
methadone-speciﬁc death. Clients should be alerted that their risk of methadone-speciﬁc death increases as they
age.
What is known already
• Record-linkage studies internationally have shown the value of
opioid substitution therapy as a treatment which reduces sub-
stantially clients’ risk of drug-related death (DRD); also that DRD-
rates are lower for female opioid users and increase with age beyond
35 years but that the female advantage is much reduced for older
clients.
• Despite harm reduction measures, such as opioid substitution
therapy, UK’s DRDs have increased markedly in the past decade, in a
strongly age-related manner.
• One powerful record-linkage study on Scotland’s methadone-pre-
scription clients in 2009–2013 has shown that their adjusted hazard
ratios for methadone-speciﬁc DRD increased sharply by age-group,
irrespective of gender.
What this study adds
• By analysing the opioid-speciﬁcity of deaths for England’s National
Drug Treatment Monitoring System (NDTMS) cohort of nearly
130,000 opioid users who started a prescribing treatment modality,
predominantly methadone, during 1 April 2005 to 31 March 2009,
we conﬁrmed that their hazard ratios for methadone-speciﬁc DRDs
also increased sharply by age-group.
• Importantly, nearly half of the cohort’s person-years were aged 35+
years; and age-eﬀects persisted after adjustment for risk-behaviours.
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• By pooling results from the two major UK studies, we showed that
opioid-dependent clients’ hazard ratio for methadone-speciﬁc death
nearly doubled at 35–44 years (compared with 25–34 years); and
quadrupled at 45+ years.
Introduction
In the past decade, record-linkage studies in the UK and inter-
nationally have not only shown the value of opioid substitution therapy
as a treatment which reduces substantially clients’ risk of drug-related
death (DRD), by half (95% CI: 0.38 to 0.51) for those with a history of
injecting (Pierce et al., 2016); but also that DRD-rates are lower for
female opioid users; increase with age beyond 35 years; and yet the
female advantage is reduced for older clients (Bird, Robertson, &
Strang, 2010; Cornish, Macleod, Strang, Vickerman, & Hickman, 2010;
Cousins et al. 2011; Degenhardt et al., 2011; Kimber et al., 2010; King,
Bird, Overstall, Hay, & Hutchinson, 2013; King, Bird, Overstall, Hay, &
Hutchinson, 2014; Merrall et al. 2012; Pierce et al., 2016; Pierce, Bird,
Hickman, & Millar, 2015; Strang, Hall, Hickman, & Bird, 2010).
To assess the role of prescribed methadone in explaining the above
demographic inﬂuences, Gao et al. (2016) considered age-group and
gender, in addition to prescription source (general practitioner, other-
source) and quintile for the quantity of prescribed methadone, as being
potentially informative about the 361 methadone-speciﬁc DRDs ex-
perienced by 33,000 methadone-prescription clients in Scotland during
121,000 person-years of follow-up in 2009 to 2013. Their analysis re-
vealed a steeply increased hazard by age-group, irrespective of gender
(which was not prognostic) and that the top quintile for the baseline
quantity of prescribed methadone conferred additional hazard for me-
thadone-speciﬁc DRDs.
Relative to 25–34 year olds in the Scottish methadone-prescription
cohort, the adjusted hazard ratio (HR) for methadone-speciﬁc deaths
was 0.5 (95%CI: 0.3–1.0) for those aged under 25 years, 1.9 (95% CI:
1.5–2.4) at 35–44 years and 2.9 (95% CI: 2.2–3.9) at 45+ years of age.
Eleven percent of Scotland’s methadone-prescription clients were aged
45+ years.
The ﬁrst to demonstrate how steeply the risk of methadone-speciﬁc
death increases with client-age, Scotland’s methadone-prescription co-
hort had the advantage of a national protocol in Scotland for tox-
icological reporting at forensic autopsy so that the speciﬁed opioids
were implicated in, not merely present at, DRD. However, substantial
numbers of Scotland’s two million methadone prescriptions issued over
four years lacked a Community-Health Index (CHI)-number, meaning
that they were not readily linkable to individual clients. For that reason,
Scottish clients’ periods on/oﬀ prescribed methadone could not be
analysed (Gao et al., 2016). Nonetheless, an estimated 82% of Scot-
land’s methadone clients were linkable to mortality-records because
they had at least one CHI-identiﬁed prescription (Gao et al., 2016).
Besides calling for a better understanding of methadone’s pharma-
codynamics in older clients, many with potential confounders such as
progressive physical or mental ill-health, Gao et al. (2016) noted that,
since 2006, electrocardiograms have been recommended by UK’s
Medicines and Healthcare products Regulatory Authority for older or
persistent methadone clients on higher doses. This recommendation
was made to detect prolongation of that part of the heart’s normal
electrical cycle known as the QT interval because, unlike buprenor-
phine, methadone – alone and with other drugs commonly used for co-
morbidities, especially mental health conditions: antidepressants, an-
tipsychotics, antibiotics (macrolides, quinolones, azoles), antiar-
rhythmics, protease inhibitors and the loop diuretic furosemide
(Romero et al., 2016) – is known to prolong the QT interval; and pro-
longation increases the risk of torsades de pointes and sudden cardiac
death, yet leaves no detectable trace at autopsy. Other risk factors for
corrected QT prolongation include age-related co-morbidities such as
renal impairment, heart or liver disease; and being female, see Gao
et al. (2016).
Before diving too deeply into confounders, as above, in explanation
for the strongly age-related increase in Scottish clients’ hazard of me-
thadone-speciﬁc death, we considered that it was important ﬁrst to test
the Scottish results. England’s National Drug Treatment Monitoring
System (NDTMS) cohort of nearly 130,000 opioid users who had started
a prescribing treatment modality during 1 April 2005 to 31 March 2009
enabled such testing. The calendar period for the NDTMS cohort was
immediately preceding Scotland’s (Pierce et al. 2016), thereby also
preceding the heroin drought of 2010; 47% of the NDTMS cohort’s
person-years were aged 35+ years, similar to 48% at baseline for
Scotland’s methadone-prescription cohort. Importantly, information on
NDTMS clients’ periods in/out of treatment, declared injecting and
misuse of alcohol, benzodiazepines and other drugs (Pierce et al. 2016)
could be taken into account in addition to age-group and gender. The
English cohort’s gender and age-speciﬁc mortality from causes other
than DRDs has been reported elsewhere (Pierce et al., 2015).
In this paper, for NDTMS opioid-user clients who received at least
one day of opioid agonist prescribing (OAP), we aimed to:
i) document the inﬂuence of demographic risk factors (age-group;
gender) on OAP clients’ HR for DRD, methadone-speciﬁc DRD,
heroin-speciﬁc DRD, having adjusted also for clients’ time-depen-
dent declared injecting (ever) and past-month misuse of alcohol,
benzodiazepines, and other drugs;
ii) repeat the above analysis with adjustment also for periods in/out of
treatment;
iii) pool age-related HRs for methadone-speciﬁc deaths from the
Scotland’s methadone-prescription cohort and England’s OAP co-
hort.
Methods
Data
The National Drug Treatment Monitoring System (NDTMS) provides
details on all structured treatment for substance misuse provided in
England. The cohort for this national record linkage study was identi-
ﬁed from NDTMS records collected over the study period 1st April 2005
to 31st March 2009; with linkage to mortality records provided that the
subject’s identiﬁer was not in a many-to-one mapping, see Fig. 1. The
Oﬃce for National Statistics (ONS) provided data on deaths occurring
during the observation period which were registered by 30 September
2011. This allowed for delays in the registration process pending in-
quest verdicts.
Records in NDTMS are created for each treatment modality received
191,312 opiate users aged 18-64 years 
idenピged from NDTMS for 1st April 
2005 to 31st Match 2009 
35,083 discarded based on 
1:many match with Police 
Naピonal Computer idenピger
129,979 subjects idenピged for 
analysis
26,250 discarded because they 
did not have a prescribing 
modality over analysis period
Fig. 1. Flow diagram of case-selection for the analysis cohort.
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by a given patient. Treatment modalities were categorised, as in Pierce
et al. (2016) into: OAP; psychosocial treatment; and residential treat-
ment. A treatment episode is deﬁned as an unbroken or contiguous
series of treatment modalities.
Data were supplied at the episode-level on: self-reported illicit drug
injecting status (past month); and an optional self-report of up to three
additional problematic psychoactive substances. In NDTMS, prescribed
opioid agonist was not diﬀerentiated as to methadone or buprenor-
phine, but the vast majority was methadone (Cornish et al., 2010).
Patients were included in the OAP cohort if they received at least
one day of prescribing treatment over the study period and were aged
18 to 64 at their inclusion-date. The cohort analysed here is a sub-co-
hort of that described by Pierce et al. (2016) who checked thoroughly
on the proportionality of DRD hazards.
The NDTMS cohort was linked to ONS mortality records. For each
death record, the underlying cause of death is coded according to the
ICD-10 framework with DRDs deﬁned by ICD-10 codes according to
ONS’s deﬁnition (Oﬃce for National Statistics, 2017). Additionally, for
each death, the ONS created ﬂags to indicate whether ‘methadone’ and/
or ‘heroin’ and/or ‘buprenorphine’ were mentioned on the death cer-
tiﬁcate.
In England, the opioid-speciﬁcity of DRDs is determined by the
drugs which are mentioned on the death-certiﬁcate. As the majority of
DRDs are registered following a coroner’s inquest, the text on the cor-
oner’s death certiﬁcate is used by ONS to code all of the substances
involved in the death. Analogous to Gao et al. (2016), we deﬁne me-
thadone-speciﬁc DRDs as those in which methadone was mentioned but
neither heroin nor buprenorphine; and heroin-speciﬁc DRDs as those in
which heroin was mentioned but neither methadone nor buprenor-
phine. If opioid was mentioned on a DRD death certiﬁcate without
further speciﬁcation, which occurs for around 5% of England’s opioid-
related DRDs (Oﬃce for National Statistics, 2017), the death was
counted as DRD; but neither as methadone-speciﬁc DRD nor as heroin-
speciﬁc DRD. Similarly, any DRD which mentioned buprenorphine was
counted as DRD; but neither as methadone-speciﬁc DRD nor as heroin-
speciﬁc DRD. However, buprenorphine is so infrequently mentioned in
England and Wales as to be not separately tabulated by ONS even for
DRD registrations in 2016.
Treatment and mortality data were linked using a minimal identiﬁer
in each database (initials, date of birth, gender) and government region
of usual residence. Prior analysis indicated that 22% of minimal iden-
tiﬁers in the treatment population were shared by one or more in-
dividuals on the criminal records database which contributed to the
cohort’s derivational linkages (Pierce et al., 2016). These minimal
identiﬁers were removed from the analysis cohort because the subject’s
drug treatment record could not be reliably linked to his/her mortality
record. The resulting OAP cohort comprised in 129,979 linked in-
dividuals, see Fig. 1.
Data were rendered anonymous to the research team, via irrever-
sible encryption of identifying information, prior to their release by
source organizations.
Statistical analysis
Descriptive life-table analysis (per 10,000 person-years of follow-
up) was undertaken for the outcomes: any DRD; DRD that mentioned
methadone on the death certiﬁcate but neither heroin nor buprenor-
phine (methadone-speciﬁc DRD); and DRD that mentioned heroin on
the death certiﬁcate but neither methadone nor buprenorphine (heroin-
speciﬁc DRD).
Subjects entered the risk-set at their earliest OAP-treatment date
during the period 1st April 2005 to 31st March 2009. They left the risk
set at the earlier of their date of death, 65th birthday, or the end of data
collection (31st March 2009).
Time-dependent covariates for the OAP cohort were time-updated
age (categorised as 18–24; 25–34, 35–44, 45–64 years) and patient-
reported behavioural covariates, collected at the beginning of each
treatment episode and deﬁned from their date of ﬁrst report, namely:
injecting status; problematic use of alcohol, benzodiazepines, crack
cocaine, cocaine powder and amphetamines (the latter two substances
combined due to a low level of reporting). A time-dependent covariate
for being in/out of treatment was also created to indicate whether the
patient was enrolled in any structured treatment (prescribing or
otherwise) using the start and end dates for treatment modality.
For each outcome, cause-speciﬁc Cox proportional hazard ratios
were estimated by censoring other deaths and using covariates as
above. Interaction between age and gender was anticipated for DRDs
(Pierce et al., 2015; King et al., 2013; King et al., 2014).
When pooling the age-related HRs for methadone-speciﬁc deaths
from the Scottish and English cohorts, age-group speciﬁc weights were
derived from the information contributed per age-group by each cohort;
alternatively, a common weighting was derived from the total in-
formation across all three age-groups (< 25 years; 35–44 years; 45+
years). Please see Supplementary Information for details of both cal-
culations. In statistical terms, notice that the information which a co-
hort contributes about ln HR for a particular age-group (relative to
25–34 year olds) is deﬁned by the reciprocal of the variance of the
cohort’s estimated ln HR for that age-group.
Results
England’s OAP cohort of 129,979 prescribing modality clients was
followed-up for 378,009 person-years (pys) and experienced 1,266
DRDs, an overall rate of 33 DRDs per 10,000 pys (95% CI: 31.6–35.3),
of which 271 were methadone-speciﬁc DRDs and 473 were heroin-
speciﬁc.
Overall, the OAP cohort’s methadone-speciﬁc DRD-rate was 7 per
10,000 pys, irrespective of gender. By age-group, however, the me-
thadone-speciﬁc DRD-rate was 3.5 (95% CI: 2.7–4.4) at 18–34 years,
8.9 (CI: 7.3–10.5) at 35–44 years and 18 (CI: 13.8–21.2) at 45+ years;
whereas the heroin-speciﬁc DRD-rate of 12.5 per 10,000 pys was un-
changed by age, but was signiﬁcantly higher for males than females, see
Table 1.
None of the behavioural risk-factors in Table 1 had a materially
diﬀerent inﬂuence on heroin-speciﬁc versus methadone-speciﬁc DRDs,
apart from having ever injected (a more accentuated HR for heroin-
speciﬁc deaths). Table 2 shows that the doubling of DRD-risk when out-
of-treatment partitions as a nearly quadrupled risk of heroin-speciﬁc
DRD but non-signiﬁcant 20% out-of-treatment reduction in methadone-
speciﬁc DRD risk. Other covariate inﬂuences are unchanged from
Table 1.
The weights used for the Scottish methadone-prescription cohort in
pooling age-group speciﬁc HRs (see Introduction for the Scottish results
to be pooled) were 43% for under 25 years of age, 63% for 35–44 year
olds, and 55% at 45+ years; alternatively, a common weighting of 58%
may be preferred, which is based on the sum of information across age-
groups. The alternatives agree inferentially, see Supplementary in-
formation.
Relative to clients aged 25–34 years, the pooled HRs for methadone-
speciﬁc deaths across Scotland’s methadone-prescription client cohort
and the English prescribing cohort from Table 1 were: under 25 years of
age, 0.87 (95% CI: 0.56–1.35); at 35–44 years, 2.14 (95% CI:
1.76–2.60); and at 45+ years, 3.75 (95% CI: 2.99–4.70).
Discussion
Summary of main ﬁndings and recommendations
The OAP cohort allowed us to validate, for England, the novel re-
cord-linkage ﬁndings from Scotland that opioid using clients’ hazard of
methadone-speciﬁc death rises steeply with age and is independent of
gender. In addition, we have shown that these demographic inﬂuences
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hold up when adjustment is made for a triad of declared behavioural
characteristics (injecting, misuse of alcohol and misuse of benzodiaze-
pines) and for periods in/out of opioid substitution therapy, factors not
addressed in Scotland’s methadone-prescription cohort.
Next, we pooled age-related HRs from the two national cohorts for
added precision so that, relative to 25–34 year olds, the OAP clients’
pooled HRs for methadone-speciﬁc deaths in the UK were doubled at
35–44 years and nearly quadrupled at 45+ years.
We therefore recommend that consideration be given to reviewing
older clients’ methadone dosage in the context of the patient’s cardio-
vascular, respiratory and liver or renal related co-morbidities (Gao
et al., 2016); and prescribed medications, including for mental health
problems (Independent Expert Group, 2017). Gao et al. (2016) re-
commended that a representative sample of 45+ year old methadone
clients be oﬀered electrocardiograms (ECG) to establish what propor-
tion of them (1%, 5% or 10%) had prolongation of their corrected QT
segment (by 60 milliseconds or to above 500 milliseconds). In the light
of our evidence-synthesis, we propose that this surveillance should be
extended to 35–44 year olds. We propose surveillance as the initial step
because we recognise that methadone treatment centres currently may
lack equipment to perform and qualiﬁed staﬀ to interpret ECGs and yet
may be clients’ only contact with health care systems.
Finally, we recommend that methadone clients can safeguard
themselves and their older peers by carrying a naloxone-kit (Bird,
McAuley, Perry, & Hunter, 2016; Parmar, Strang, Choo, Meade, & Bird,
2017) and ensuring that family and friends know how to intervene in
the event of overdose.
Comparability of cohorts from England and Scotland
The availability of a cohort with well over 100 methadone-speciﬁc
DRDs is a considerable strength of England’s validation study. The OAP
cohort of nearly 130,000 clients (1 April 2005–31 March 2009) and
Scotland’s methadone-prescription cohort of 33,000 clients (1 July
2009–30 June 2013) were broadly similar in terms of age-distribution,
number of methadone-speciﬁc deaths (271; 361) and average follow-up
time. Scottish clients’ age-distribution was documented at baseline only
(Gao et al., 2016); the English cohort’s was time-updated. Scotland’s
DRD-classiﬁcation, supported by a national protocol for toxicology at
forensic autopsy, is based on drugs implicated in the death. England’s
used the text on the coroner’s death certiﬁcate to code all of the sub-
stances involved in the death.
Scot;1;land’s methadone-prescription cohort had an overall DRD
rate of 63 per 10,000 pys compared with the OAP cohort’s much lower
rate of 33 DRDs per 10,000 pys. This diﬀerence may be partly ac-
counted for by injection drug use being less prevalent in England (King
et al., 2013; King et al., 2014). Under half the OAP clients had a history
of injecting (declared or undeclared), a behavioural covariate which, as
Table 1 showed, doubles clients’ hazard ratio for DRD. Unfortunately,
information on past-history of injecting was not directly available for
Scotland’s methadone-prescription cohort. Period eﬀects on DRD-rates
cannot be ruled out between 2005-2009 and 2009–2013, the second of
which coincided with a re-focusing of the UK’s drug policy away from
harm reduction towards accelerated recovery, an emphasis that has
since been moderated in the UK Government’s 2017 Drugs Strategy
(2017), see Her Majesty’s Government (2017). Importantly, the earlier
period preceded the heroin drought of 2010.
Limitations
For diﬀerent reasons, the availability of unique identiﬁers limited
linkage to about 80% of clients in the OAP cohort, see Fig. 1; and in
Scotland’s methadone-client cohort (Gao et al., 2016). As detailed in
Methods, we discarded 22% of identiﬁers from the OAP cohort where
there was evidence that two or more individuals might share the same
details. Nonetheless, it remains possible that some proportion of the
remainder might also have shared details with other individuals in their
region. Errors in matching within treatment records and in matching
Table 1
Proportional hazard analysis: DRD, methadone only and heroin only mortality associated with covariates, for opioid users who had a prescribing treatment modality over the period 1 st
April 2005 to 31 st March 2009. (N=129,979; person-years (pys)= 378,009).
DRD Methadone only Heroin only
Pys (k) Deaths CMR per
10k pys
Adjusted Hazard
Ratio [95% CI]*
P value Deaths CMR per
10k pys
Adjusted Hazard
Ratio [95% CI]*
P value Deaths CMR per
10k pys
Adjusted Hazard
Ratio [95% CI]*
P value
Age
18–24 33,588 74 22.0 0.92 [0.72, 1.18] <0.001 14 4.2 1.26 [0.70, 2.27] < 0.001 36 10.7 0.99 [0.69, 1.41] 0.796
25–34 167,045 429 25.7 REF 57 3.4 REF 202 12.1 REF
35–44 128,936 514 39.9 1.54 [1.35, 1.75] 115 8.9 2.60 [1.89, 3.57] 172 13.3 1.09 [0.89, 1.33]
45+ 48,530 249 51.3 2.08 [1.78, 2.44] 85 17.5 5.14 [3.66, 7.21] 63 13.0 1.11 [0.84, 1.48]
Gender
Male 257,948 971 37.6 REF <0.001 188 7.3 REF 0.500 390 15.1 REF <0.001
Female 120,151 295 24.6 0.73 [0.64, 0.83] 83 6.9 1.09 [0.84, 1.42] 83 6.9 0.49 [0.38, 0.62]
Injecting, ever declared
Yes 147,341 704 47.8 2.12 [1.88, 2.40] <0.001 130 8.8 1.64 [1.27, 2.13] 0.001 277 18.8 2.47 [2.00, 3.04] <0.001
No 194,901 418 21.5 REF 111 5.7 REF 135 6.9 REF
Undeclared 35,857 144 40.2 1.95 [1.61, 2.36] 30 8.4 1.47 [0.98, 2.21] 61 17.0 2.51 [1.85, 3.40]
Declared alcohol misuse
Yes 45,557 258 56.6 1.68 [1.46, 1.93] <0.001 48 10.5 1.44 [1.05, 1.98] 0.024 92 20.1 1.63 [1.29, 2.05] <0.001
No 332,542 1008 30.3 REF 223 6.7 REF 381 11.5 REF
Declared benzodiazepine misuse
Yes 54,051 258 47.7 1.39 [1.21, 1.60] <0.001 54 10.0 1.44 [1.07, 1.95] 0.017 95 17.6 1.34 [1.07, 1.69] 0.011
No 324,049 1008 31.1 REF 217 6.7 REF 378 11.7 REF
Declared crack cocaine misuse
Yes 136,746 469 34.3 0.97 [0.87, 1.10] 0.671 76 5.6 0.69 [0.52, 0.90] 0.006 170 12.4 0.91 [0.75, 1.10] 0.334
No 241,353 797 33.0 REF 195 8.1 REF 303 12.5 REF
Declared cocaine/amphetamine misuse
Yes 49,451 188 38.0 1.04 [0.89, 1.22] 0.582 41 8.3 1.15 [0.82, 1.61] 0.420 84 17.0 1.29 [1.01, 1.64] 0.038
No 328,649 1078 32.8 REF 230 7.0 REF 389 11.8 REF
* Evidence for gender and age interaction − DRD model: p= .013; methadone only model: p= .350; heroin only model: p= .062.
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these to mortality records might potentially have occurred as a con-
sequence of this but, insofar as these arose due to the random coin-
cidence of the minimal identifying information that was available in the
OAP cohort, these errors will have contributed noise to the analysis
rather than exerting any systematic eﬀect.
England, and many other countries, does not have a national pro-
tocol for toxicology and its reporting at forensic autopsy. Thus,
England’s classiﬁcation of methadone-speciﬁc deaths is on a less ﬁrm
basis than Scotland’s.
Details of opioid agonist prescribing were absent for the English
cohort: both which agonist (methadone versus buprenorphine) and the
quantity prescribed. We do not know directly what proportion of OAP
clients received methadone, although we expect the proportion to have
been high, around 90% (Cornish et al., 2010). Scotland’s age-related
HRs for methadone-speciﬁc DRD increased just as steeply whether
prescribed quantity of methadone was, or was not, ﬁtted. Hence, the
OAP cohort’s absence of methadone dose does not undermine our va-
lidation. Importantly, the English OAP cohort’s additional adjustment
for behavioural covariates and for periods in/out of treatment, see also
Pierce et al. (2016), did not mitigate the steep age-relatedness in ad-
justed HRs for methadone-speciﬁc deaths either.
Unlike for demography, self-reporting of behavioural covariates
could lead to HRs that are closer to 1 than would be the case without
mis-classiﬁcation and so some residual behavoural confounding cannot
be ruled out.
The absence from both record-linkage studies of information on
ageing clients’ co-morbidities and speciﬁc other prescriptions which
may interact with methadone is a limitation to be addressed in further
research. In making a case for the public beneﬁt of linking-in metha-
done clients’ hospitalizations and speciﬁed other prescribing records,
applicants can now cite, in their support, the UK’s evidence-synthesis on
ageing opioid users’ risk of methadone-speciﬁc death.
Further research
Similarly large national cohort studies of OAP clients, investigating
how age-group and gender inﬂuence the opioid-speciﬁcity of client-
deaths, are needed for robust generalizations outside of the UK.
Within the UK, a strong public interest case can now be made for
more extensive record-linkage studies to include, besides mortality and
DRDs’ opioid-speciﬁcity, OAP clients’ or methadone-prescription cli-
ents’ history of hospitalizations (by which to infer co-morbidities), di-
agnosed carriage of blood-borne viruses (particularly the most pre-
valent, Hepatitis C virus), and selected co-prescribing (including for
mental health conditions).
Without research, as above, into possible confounders, we can only
speculate, as did Gao et al. (2016), on the underlying cause for the now-
conﬁrmed steep age-gradient for methadone-speciﬁc DRDs: corrected
QT prolongation, renal or liver impairment, or some other aspect of the
pharmacology of methadone in older clients that makes for a longer
half-life. Indeed, it is the report of one of the authors that some me-
thadone patients have expressed to him the opinion that, as they age,
they don’t seem to need as high a methadone dose (JRR, personal
communication). In short, cardiac and pulmonary co-morbidities, as
well as liver and renal disease, may contribute to methadone-speciﬁc
DRDs.
As too little is known about the gender- and age-speciﬁc pharma-
cology of methadone in older opioid-dependent clients, we suggest a
pharmacokinetic study that simultaneously assesses methadone’s
pharmacokinetic properties in diﬀerent settings of clients’ cardiac, re-
spiratory, renal or liver impairment. Additionally, given the concern for
sudden cardiac death linked to QTc prolongation and subsequent ar-
rhythmias, extended monitoring in the form of Holter monitoring or
loop recorders could further elucidate older clients’ risk when pre-
scribed methadone.
Table 2
Proportional hazard analysis: DRD, methadone only and heroin only mortality associated with treatment and covariates, for opioid users who had a prescribing treatment modality over
the period 1 st April 2005 to 31 st March 2009. (N=129,979; person-years (pys)= 378,009).
DRD Methadone only Heroin only
Pys (k) Deaths CMR
per 10k
pys
Adjusted Hazard
Ratio [95% CI]*
P value Deaths CMR per
10k pys
Adjusted Hazard
Ratio [95% CI]*
P value Deaths CMR per
10k pys
Adjusted Hazard
Ratio [95% CI]*
P value
Treat
In 283,801 790 27.8 REF <0.001 217 7.6 REF 0.122 226 8.0 REF <0.001
Out 94,298 476 50.5 1.98 [1.76, 2.23] 54 5.7 0.79 [0.58, 1.07] 247 26.2 3.72 [3.09, 4.49]
Age
18–24 33,588 74 22.0 0.90 [0.70, 1.15] <0.001 14 4.2 1.27 [0.71, 2.28] < 0.001 36 10.7 0.93 [0.65, 1.33] 0.379
25–34 167,045 429 25.7 REF 57 3.4 REF 202 12.1 REF
35–44 128,936 514 39.9 1.57 [1.38, 1.78] 115 8.9 2.59 [1.88, 3.56] 172 13.3 1.13 [0.92, 1.39]
45+ 48,530 249 51.3 2.18 [1.86, 2.55] 85 17.5 5.08 [3.62, 7.13] 63 13.0 1.22 [0.92, 1.62]
Gender
Male 257,948 971 37.6 REF <0.001 188 7.3 REF 0.531 390 15.1 REF <0.001
Female 120,151 295 24.6 0.74 [0.65, 0.85] 83 6.9 1.09 [0.84, 1.41] 83 6.9 0.52 [0.41, 0.65]
Injecting, ever declared
Yes 147,341 704 47.8 2.17 [1.91, 2.45] <0.001 130 8.8 1.63 [1.26, 2.12] 0.001 277 18.8 2.58 [2.09, 3.18] <0.001
No 194,901 418 21.5 REF 111 5.7 REF 135 6.9 REF
Undecla-
red
35,857 144 40.2 1.77 [1.46, 2.15] 30 8.4 1.51 [1.01, 2.28] 61 17.0 2.08 [1.54, 2.83]
Declared alcohol misuse
Yes 45,557 258 56.6 1.73 [1.51, 1.99] <0.001 48 10.5 1.43 [1.04, 1.96] 0.026 92 20.1 1.75 [1.39, 2.21] <0.001
No 332,542 1008 30.3 REF 223 6.7 REF 381 11.5 REF
Declared benzodiazepine misuse
Yes 54,051 258 47.7 1.43 [1.25, 1.65] <0.001 54 10.0 1.43 [1.06, 1.94] 0.020 95 17.6 1.45 [1.15, 1.82] 0.002
No 324,049 1008 31.1 REF 217 6.7 REF 378 11.7 REF
Declared crack cocaine misuse
Yes 136,746 469 34.3 0.97 [0.86, 1.09] 0.631 76 5.6 0.69 [0.52, 0.90] 0.007 170 12.4 0.91 [0.75, 1.11] 0.345
No 241,353 797 33.0 REF 195 8.1 REF 303 12.5 REF
Declared cocaine/amphetamine misuse
Yes 49,451 188 38.0 1.06 [0.91, 1.24] 0.454 41 8.3 1.15 [0.82, 1.60] 0.429 84 17.0 1.33 [1.05, 1.69] 0.018
No 328,649 1078 32.8 REF 230 7.0 REF 389 11.8 REF
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Conclusion
Only formal studies will resolve what can and should be done to
moderate opioid dependent clients’ increased risk of methadone-spe-
ciﬁc death as they age. Consistent ﬁndings in two major UK cohorts
represent suﬃcient grounds for methadone prescribers, at least in the
UK, to alert clients that their risk of methadone-speciﬁc death increases
as they age − for reasons that we do yet fully understand. Review of
older clients’ methadone dose in the light of co-morbidities and pre-
scribed other medications may be worthwhile with consideration given,
for some clients, to switching their opioid substitution formulation
(McCance-Katz, 2011; Jolley et al., 2015).
Funding
Medical Research Council grant G1000021 for the NIQUAD
(Nationally Integrated Quantitative Understanding of Drug-harms)
Addictions Cluster. The funder had no role in the decision to publish
this paper.
Contributions
SMB proposed the validation study for England to MP & TM who are
its guarantors; TM holds privacy access permission for linkage of
National Drug Data Warehouse (2005–2009) to Oﬃce for National
Statistics mortality records, which was conducted in autumn 2011 to
allow 2.5 years for the delayed registration of drugs-related deaths.
SMB & JRR had instigated inquiries into Scotland’s methadone pre-
scribing and a possible link to Scotland’s increased number of metha-
done-speciﬁc deaths and been co-authors of the initial study which
demonstrated increased hazard for older clients; MP re-programmed
previous analyses of the English cohort to focus on methadone-speciﬁc
deaths; all authors contributed to the writing, referencing and review of
the manuscript.
Data sharing statement
The authors are bound by the conditions imposed on their access to
the Drugs Data Warehouse but can assist others in how to achieve si-
milar access.
Transparency
The lead author (as the manuscript’s guarantor) aﬃrms that the
manuscript is an honest, accurate, and transparent account of the study
being reported; that no important aspects of the study have been
omitted; and that any discrepancies from the study as planned (and, if
relevant, registered) have been explained.
Ethics/privacy access approval
Data were extracted from the Drug Data Warehouse for a cohort of
opioid users, aged 18 to 64 years, actively using or being treated for
opioid use, in England over the period 1 st April 2005 to 31 st March
2009. Deaths occurring in the cohort were established by case linkage
to national mortality records. Data were rendered anonymous to the
research team, via irreversible encryption of identifying information,
prior to their release by source organisations.
Use of mortality records was approved by the Oﬃce for National
Statistics Microdata Release Panel. Use of data from the Drug Data
Warehouse was authorised by those organisations providing data. The
NHS Central Oﬃce for Research Ethics Committees and The University
of Manchester Research Ethics Committee advised that further approval
was not required for a study of this type.
Conﬂicts of interest
SMB served on Scotland’s National Naloxone Advisory Group and
was one of three co-principal investigators for the MRC-funded N-
ALIVE pilot Trial of naloxone-on-release. SMB holds GSK shares. JRR
chaired Scotland’s National Forum on Drugs-related Deaths and serves
on the committee which is updating UK’s opioid prescribing re-
commendation. SMB and JRR were co-authors of the Scottish study for
which this study provides validation.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.drugpo.2018.02.005.
References
Bird, S. M., Robertson, J. R., & Strang, J. (2010). Drug-related deaths: What needs to be
done. Straight Statistics http://straightstatistics.org/article.drug-related-deaths-what-
now-needs-to-be-done. (Accessed 31 May 2016).
Bird, S. M., McAuley, A., Perry, S., & Hunter, C. (2016). Eﬀectiveness of Scotland’s
National Naloxone Programme for reducing opioid-related deaths: a before
(2006–2010) versus after (2011–2013) comparison. Addiction, 111, 883–891. http://
dx.doi.org/10.1111/add.13265.
Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010). Risk of death
during and after opiate substitution treatment in primary care: Prospective ob-
servational study in UK General Practice Research Database. British Medical Journal,
341, c5475.
Cousins, G., Teljeur, C., Motterlini, N., McCowan, C., Dimitrov, B. D., & Fahey, T. (2011).
Risk of drug-related mortality during periods of transition in methadone main-
tenance: A cohort study. Journal of Substance Abuse Treatment, 41, 252–260.
Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., et al. (2011).
Mortality among regular or dependent users of heroin and other opioids: A systematic
review and meta-analysis of cohort studies. Addiction, 2011(106), 32–51.
Gao, L., Dimitropoulou, P., Robertson, J. R., McTaggart, S., Bennie, M., & Bird, S. M.
(2016). Risk-factors for methadone-speciﬁc deaths in Scotland’s methadone-pre-
scription clients between 2009 and 2013. Drug and Drug Dependence, 167, 214–223.
Her Majesty’s Government. (2017). 2017 Drug Strategy. Home Oﬃce, 14 July 2017.
Independent Expert Group (chair: Professor Sir John Strang). (2017). Drug misuse and
dependence. UK guidelines on clinical management. Public Health England, July
2017. See Section 4.7.4.1 of https://www.gov.uk/government/publications/drug-
misuse-and-dependence-uk-guidelines-on-clinical-management. (Accessed 28 July
2017).
Jolley, C. J., Bell, J., Raﬀerty, G. F., Moxham, J., & Strang, J. (2015). Understanding
heroin overdose: A study of the acute respiratory depressant eﬀects of injected
pharmaceutical heroin. PUBLIC LIBRARY OF SCIENCE. http://dx.doi.org/10.1371/
journal.pone.0140995.
Kimber, J., Copeland, L., Hickman, M., Macleod, J., McKenzie, J., De Angelis, D., et al.
(2010). Survival and cessation in injecting drug users: Prospective observational
study of outcomes and eﬀect of opiate substitution therapy. British Medical Journal,
341, c3172.
King, R., Bird, S. M., Overstall, A., Hay, G., & Hutchinson, S. J. (2013). Injecting drug
users in Scotland, 2006: Listing, number, demography, and opiate-related death-
rates. Addiction Research and Theory, 21, 235–246.
King, R., Bird, S. M., Overstall, A., Hay, G., & Hutchinson, S. J. (2014). Estimating pre-
valence of injecting drug users and associated heroin-related death rates in England
using regional data and incorporating prior information. Journal of the Royal
Statistical Society Series A (Statistics in Society), 177, 1–28.
McCance-Katz, E. F. (2011). (R)-methadone versus racemic methadone: What is best for
patient care? Addiction, 106, 687–688.
Merrall, E. L. C., Bird, S. M., & Hutchinson, S. J. (2012). Mortality of those who attended
drug services in Scotland 1996–2006: Record linkage study. International Journal of
Drug Policy, 23, 24–32.
Oﬃce for National Statistics (2017). Deaths related to drug poisoning in England and Wales:
2016 registrations. Deaths related to drug poisoning in England and Wales from 1993
onwards, by cause of death, sex, age and substances involved in the death. Oﬃce for
National Statistics Statistical Bulletin See https://www.ons.gov.uk/
peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/
deathsrelatedtodrugpoisoninginenglandandwales/2016registrations. (Accessed 7
August 2017).
Parmar, M. K. B., Strang, J., Choo, L., Meade, A. M., & Bird, S. M. (2017). Randomized
M. Pierce et al. ,QWHUQDWLRQDO-RXUQDORI'UXJ3ROLF\²

controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose
deaths. Addiction, 112, 502–515.
Pierce, M., Bird, S. M., Hickman, M., & Millar, T. (2015). National record-linkage study of
mortality for a large cohort of opiate users ascertained by drug treatment or criminal
justice sources, 2005–2009. Drug and Alcohol Dependence, 146, 17–23.
Pierce, M., Bird, S. M., Hickman, M., Marsden, J., Dunn, G., Jones, A., et al. (2016).
Impact of treatment for opioid dependence on fatal drug-related poisoning: A na-
tional cohort study in England. Addiction, 111, 298–308.
Romero, J., Baldinger, S. H., Goodman-Meza, D., Engstrom, K., Valencia, C. R., Golive, A.,
et al. (2016). Drug-induced torsades de pointes in an underserved urban population.
Methadone: Is there therapeutic equipoise? Journal of Interventional Cardiac
Electrophysiology, 45, 37–45.
Strang, J., Hall, W., Hickman, M., & Bird, S. M. (2010). Impact of supervision of me-
thadone consumption on deaths related to methadone overdose (1993–1998):
Analysis using OD4 index in England and Scotland. British Medical Journal, 341(640),
c4851.
M. Pierce et al. ,QWHUQDWLRQDO-RXUQDORI'UXJ3ROLF\²

